Upon further research found "Moreover, Teva calls on Sandoz/Momenta to make samples of M356 publicly
available, so that interested researchers can apply the latest methods to further investigate
complex medicine “sameness” in general, and specifically make comparisons between
M356 and Copaxone®." this in Teva's comment to FDA on 9/9/2014. Their gene expression info irrelevant to Momentas copy- They obviously have not had anything to compare it to.
New gene expression to sway FDA and public sentiment? Will it work?-seams to keep FDA approval at bay for now
Do not think too much. The problem is the Pasadena plant. It robs peter to pay Paul ( ammonia ) do not believe management can turn it around , could they start to produce ammonia at Pasadena for their own use- heck its in Texas where there is a little nat gas. Took my lumps,GLTA
Well they lost alot of money at Pasadena , kept most of the cash they did make, next few quarters look bad, so they took all cash this qtr and gave *&%#* to the unit holders. Wow driven company in the ground- dont think I care for the next MLP this management cobbles together from the parent company.
Allways see timing of earnings as non event. Good is good, Bad is bad- one day more of trading only important for options. CC today at 1;30pm
Distributions will be down due to capital requirements, previous release said not to expect distribution of all cash available for this reason. Management has been dead wrong on past guidance for pricing and distributions.Pasadena has been an anchor, only benefit is most people pick up at facility keeping transportation costs down.
Management thinks this will give clearer view of their potential, which it might then lead to a better response for any secondary offering IMO Supreme court review in October might be small catalyst.. If their science is so good and through can shareholders expect a minimum of six years FDA review of any future ANDA's?
After seeing the pricing UAN received for the last Qtr, It looks to be a hedge for the downside.
Well. Damn hate being right. Same drivel of working with FDA , Copaxone generic looks to go all the way till October for the supreme court and then still no FDA approval. They are starting trials with Baxter for their lead product. Guess Baxter saw the problem they are having with Copaxone candidate. And they are dropping an Oncology program.. Waiting till October to revisit any potential increase. Good news is they still have enough cash not to push thru a secondary offering, and if they get approval any time this year they will not do one.
my concern with the spike up in ammonia is as a feed-stock for the Pasadena plant , which to me says costs are high and the AS pricing has remained low which might just give the operation of the plant as a big negative for the qtr/year.
The partnership expects to distribute less than all of the cash available for distribution in the second quarter of 2014, in order to replenish working capital reserves that were diminished by $20 million of negative cash available for distribution in the fourth quarter of 2013. from their press release.
Not there either, but if they do my holdings will get bumped up from reinvesting. The only thing I like is that nat gas under 4 for the next qtr.
not for last qtr numbers. And AS pricing was still low for the pasadena plant.Still no profit there? will see in a few weeks
Like the way you think. Surprised by sub 4 nat gas. But i've seen managment grasp defeat out of the jaws of victory. In other words ,Management has proved to be very inept in the past. Hope the new people do help.
Or Pwc says the company has provided ALL missing documents / information . that the special committee could not find. That was my exit point. saved me a few bucks. Now its entertainment. till then. And if a YMB is a microcosm for the world then no wonder there is so much violence. Do unto others-look up the rest.
unless he is wrong. Management has not won my confidence to even add at these levels.
Than Blackberry can work with? Oracle maybe, the new passport size can hold spread sheets and how interactive, to be able to pull an inventory listing and talk and change items all standing in the warehouse/office or field.Securely.